Purification of IgM Monoclonal Antibodies - Manufacturing challenges surround the use of IgM monoclonal - BioPharm International


Purification of IgM Monoclonal Antibodies
Manufacturing challenges surround the use of IgM monoclonal

BioPharm International Supplements


Industry experience is insufficient at present to identify a standard platform for IgM purification, but the tools available to process developers provide an abundance of effective options. Either hydroxyapatite or cation exchange may support effective capture, depending on the properties of a particular IgM. The high capacity and resolution of monolithic ion exchangers at high volumetric flow rates—despite the large size of IgM—make them a compelling process option at any point in a purification process. All methods discussed in this study are potential candidates for aggregate removal, and their capabilities can be enhanced, if necessary, by the presence of PEG. Together, these tools provide a level of purification, recovery, and throughput that rival the best commercial IgG purification procedures. Far from being a liability, the lack of an affinity step makes a positive contribution to overall process economy.

PETE GAGNON is the chief scientific officer of Validated Biosystems, San Clemente, CA, http://www.validated.com/, FRANK HENSEL is the managing director of Patrys GmbH, Würzburg, Germany, and RICHARD RICHIERI is the vice president of manufacturing and research and development at Avid Bioservices, Inc., Tustin, CA.


1. Bieber M, Twist C, Bhat N, Teng N. Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro. Pediatr Blood Cancer. 2007;48:380–6.

2. Irie R, Ollila D, O'Day S, Morton D. Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol Immunother. 2004;53:110–17.

3. Azuma Y, Ishikawa Y, Kawai S, Tsunenari T, Tsunoda H, Igawa T, et al. Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma. Clin Cancer Res. 2004;13:2745–50.

4. Vollmers H, Zimmermann U, Krenn V, Timmermann W, Illert B, Hensel F, et al. Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopatho-logical results. Oncol Rep. 1998;5:549–52.

5. Randall T, King L, Corley R. The biological effects of IgM hexamer formation. Eur J Immunol. 1990;20:1971–9.

6. Johnstone A, Thorpe R. Immunochemistry in practice. 2nd ed. Oxford: Blackwell Scientific Publications; 1987.

7. Gagnon P. Purification tools for monoclonal anti-bodies. Tucson: Validated Biosystems; 1996.

8. Garcia-Gonzalez M, Bettinger S, Ott S, Oliver P, Kadouche J, Pouletty P. Purification of a murine IgG3 and IgM monoclonal antibodies by euglobulin precipitation. J Immunol Met. 1988;111:17–23.

9. Middaugh C, Litman G. Effects of solutes on the cold-induced solubility of monoclonal cryoglobulins. J Biol Chem. 1977;252:8002–6.

10. Palombo G, Vedoliva A, Fassina G. Affinity purification of immunoglobulin M using a novel synthetic ligand. J Chromatogr B. 1998;715:137–45.

11. Fassina G, Palombo G, Verdoliva A, Ruvo M. Affinity purification of immunoglobulins using Protein A mimetic (PAM). In: Walker J, editor. The protein protocols handbook. 2nd ed. Totowa, NJ: Humana Press; 2002. p. 1013–24.

12. Nethery A, Raison R, Easterbrook-Smith S. Single-step purification of immunoglobulin M on C1q-Sepharose. J Immunol Met. 1990;126:57–60.

13. Ohta M, Okada M, Yamashina I, Kawasaki T. The mechanism of carbohydrate-mediated comple-ment activation by the serum mannan-binding protein. J Biol Chem. 1990;265:1980–4.

14. Nevens J, Mallia A, Wendt M, Smith P. Affinity chromatographic purification of immunoglobulin M antibodies utilizing immobilized mannan binding protein. J Chromatogr. 1992;597:247–56.

15. Gagnon P, Hensel F, Andrews P, Richieri R. Recent advances in the purification of IgM monoclonal antibodies [presentation]. Third Wilbio Confer-ence on Purification of Biological Products; 2007 Sep 24-26 [cited 2008 Feb 3]; Waltham, MA.

16. Yamakawa Y, Chiba J. High performance liquid chromatography of mouse monoclonal antibodies on spherical hydroxyapatite beads. J Liq Chromatogr. 1988;11(3):665–81.

17. Aoyama K, Chiba J. Separation of molecular forms of mouse IgA and IgM monoclonal antibodies by high performance liquid chromatography on spherical hydroxyapatite beads. J Immunol Met. 1993;162(2):201–10.

18. Coppola G, Underwood J, Cartwright G, Hearn M. High performance liquid chromatography of amino acids, peptides, and proteins. XCIII. Comparison of methods for the purification of mouse monoclonal immunoglobulin M autoantibodies. J Chromatogr A. 1989;476:269–90.

19. Jacobina M, Santarellia X, Laroche-Trineaua J, Clofent-Sancheza G. Production of a human monoclonal IgM directed against human cardiac myosin in a hollow-fiber bioreactor for membrane anion exchange chromatography purification in one-step. Human Antibodies. 2004;13:69–79.

20. Santarellia X, Domergueb F, Clofent-Sanchez G, Dabadied M, Grisselye R, Cassagne C. Characterization and application of new macroporous membrane ion exchangers. J Chromatogr B. 1998;706:13–22.

21. Brne P, Podgornik A, Benãina K, Gabor B, ·trancar A, Peterka M. Fast and efficient separation of immunoglobulin M from immunoglobulin G using short monolithic columns. J Chromatogr A. 2007;1144:120–5.

22. Hahn R, Panzer M, Hansen E, Mollerup J, Jungbauer A. Mass transfer properties of monoliths. Sep Sci Technol. 2002;37(7):1545–56.

23. Strancar A, Podgornik A, Barut M, Necina R. Short monolithic columns as stationary phases for biochromatography. Adv Biochem Eng Biotechnol. 2002;76:50–5.

24. Zhou J, Tressel T. Basic concepts in Q membrane chromatography for large-scale antibody production. Biotechnol Prog. 2006;22(2):341–9.

25. Zhou J, Tressel T, Gottschalk U, Solamo F, Pastor A., Dermawan S, et al. New Q membrane scale-down model for process-scale antibody purification. J Chromatogr A. 2006;1134:66–73.

26. Gagnon P, Richieri R, Zaidi S, Aolin F. A comparison of microparticulate, membrane, and monolithic anion exchangers for polishing applications in the purification of monoclonal antibodies [poster]. IBC International Conference and Exposition; 2007 Oct 1–4; Boston, MA.

27. Gagnon P, Richieri R, Zaidi S, Sevilla R, Brinckman A. A high speed monolithic assay for IgM quantitation in cell culture production and purification process monitoring [poster]. Third Wilbio Conference on Purification of Biological Products, 2007 Sep 24–26; Waltham, MA.

28. Abdullah M, Davies R, Hill J. The application of DNA-cellulose chromatography in the isolation of immunoglobulin M and C4b-biding protein. J Chromatogr. 1985;347:129–36.

29. Gagnon P, Grund E, Linbäck T. Large scale process development for hydrophobic interaction chromatography, Part 1: Gel selection and development of binding conditions. BioPharm. 1995;8(3):21–7.

30. Chen F, Naeve G, Epstein A. Comparison of Mono-Q, Superose 6, and ABx fast protein liquid chroma-tography for the purification of IgM monoclonal antibodies. J Chromatogr. 1988;444:153–64.

31. Henniker A, Brastock K. Purification of two monoclonal antibodies of the IgM class by hydroxyapatite and gel filtration. Biomed Chromatogr. 1993;7:121–5.

32. Bouvet J, Pires R, Pilot J. A modified gel filtration technique producing an unusual exclusion volume of IgM: a simple way of preparing monoclonal IgM. J Immunol Met. 1984;66:299–305.

33. Clezardin P, Bougro G, MacGregor J. Tandem purification of IgM monoclonal antibodies by ion exchange and gel fast protein liquid chromatography. J Chromatogr. 1986;354:425–33.

34. Clezardin P, Hunter N, MacGregor I, MacGregor J, Pepper D, Dawes J. Tandem purification of mouse IgM monoclonal antibodies produced in vitro using anion exchange and gel fast liquid protein chromatography. J Chromatogr. 1986;358:209–18.

35. Luellau E, Marison W, von Stockar U. Ceramic hydroxyapatite: a new tool for separation and analysis of IgA monoclonal antibodies. In: Carondo MJT, Griffiths B, Moreira JLP, editors. Animal Cell Technology. Dordrecht, the Netherlands; Kluwer Academic Publishers: 1997. p. 265–69.

36. Luellau E, von Stockar U, Vogt S, Freitag R. Development of a downstream process for isolation and separation of immunoglobulin monomers, dimers, and polymers from cell culture supernatant. J Chromatogr A. 1998;796:165–75.

37. Gagnon P, Ng P, Aberrin C, Zhen J, He J, Mekosh H, et al. A ceramic hydroxyapatite based purification platform: simultaneous removal of leached Protein A, aggregates, DNA, and endotoxins. BioProcess Int. 2006;4(2):50–60.

38. Gagnon P, Richieri R, Zaidi S. Nonionic polymer enhancement of aggregate removal by ion exchange and hydroxyapatite chromatography [presentation]. Twelfth Waterside Conference; 2007 Apr 23–25; San Juan, Puerto Rico.

39. Gagnon P, Godfrey B, Ladd D. Method for obtaining unique selectivities in ion exchange chromatography by addition of organic polymers to the mobile phase. J Chromatogr A. 1996;743:51–5.

40. US Food and Drug Administration. Center for Drug Evaluation and Research. Inactive ingredient search for approved drug products [database]. Rockville, MD; 2007 Oct 31 [cited 2008 Feb 3].

41. Arakawa T, Timasheff S. Mechanism of polyethylene glycol interaction with proteins. Biochemistry 1985;24:6756–62.

42. Shepard S, Brickman-Stone C, Schrimsher L, Koch G. Discoloration of ceramic hydroxy-apatite used for protein chromatography. J Chromatogr A. 2000;891:93–8.

43. Dasarathy Y. A validatable cleaning-in-place protocol for total DNA clearance from an anion exchange resin. BioPharm. 1996;9(8):41–4.

44. Ng P, McLaughlin V. Regeneration studies of anion exchange chromatography resins. BioProcess Int. 2007;5(5):52–6.

45. CHT ceramic hydroxyapatite instruction manual. Hercules, CA: Bio-Rad Laboratories; 2007.

46. Ghose S, McNerny T, Hubbard B. pH transitions in ion exchange systems: role in the development of a cation exchange process for a recombinant protein. Biotechnol Progr. 2002;18:530–7.

47. Gagnon P, Grund E. Large scale process development for hydrophobic interaction chromatography, Part 4: Controlling selectivity. BioPharm. 1996;9(5):54–64.

48. Zhen J, Gagnon P, Snyder M. Buffers and conditions for use and maintenance of CHT ceramic hydroxyapatite [poster]. Eighteenth International IBC Conference on Antibody Development and Production; 2007 Feb 28–Mar 2; Carlsbad, CA.

blog comments powered by Disqus



FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here